---
schema_version: "secwatch.filing_event.v1"
accession: "0001581280-25-000020"
form_type: "8-K"
ticker: "TWST"
cik: "0001581280"
company_name: "Twist Bioscience Corp"
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:51:31.452021+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Twist Bioscience FY2025 revenue $376.6M (+20% YoY); guides for adjusted EBITDA breakeven in Q4 FY2026

## Summary
- Record FY2025 revenue $376.6M (+20% YoY); Q4 revenue $99.0M (+17% YoY), 11th consecutive sequential growth.
- FY25 gross margin 50.7% vs 42.6% in FY24; Q4 gross margin 51.3% vs 45.1%.
- NGS segment revenue grew 23% to $208.1M; SynBio grew 17% to $145.0M; Biopharma grew 15% to $23.5M.
- Net loss narrowed to $77.7M ($1.30/share) from $208.7M ($3.60/share); adjusted EBITDA -$46.9M vs -$93.5M.
- FY2026 guidance: maintain gross margin >50%; target adjusted EBITDA breakeven by Q4 FY2026.

## SEC filing metadata
- accession: 0001581280-25-000020
- form_type: 8-K
- ticker: TWST
- cik: 0001581280
- company_name: Twist Bioscience Corp
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1581280/000158128025000020/0001581280-25-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1581280/000158128025000020/twist-20251114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001581280-25-000020
- JSON: https://secwatch.observer/filing/0001581280-25-000020.json
- Plain text: https://secwatch.observer/filing/0001581280-25-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.